Yisheng Biopharma Co. and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) recently announced a collaboration to develop an Ebola vaccine.
Yisheng has developed the PIKA adjuvant for vaccine candidates. This technology utilizes double-stranded RNA that takes on the role of pathogen recognition typically handled by Toll-Like 3 receptors.
"We are very pleased to have the USAMRIID join forces in exploring a more effective and safe Ebola vaccine, which remains a significant unmet medical need,” Yi Zhang, chairman of Yisheng Biopharma, said. “Our PIKA adjuvant has exhibited broad potential to be a revolutionary innovation as a series of novel vaccines based on this technology are under preclinical and clinical investigations against rabies, HIV, Hepatitis-B, influenza, tuberculosis and other viruses, which could significantly change the clinical practice paradigms against many human and animal virus infections. We are looking forward to updating the progress on these fronts in due course.”
Through this agreement, scientists with USAMRIID will be evaluating the technology’s potential in aiding vaccine candidates against the Ebola virus and other diseases.
"TLR-3 agonists such as PIKA adjuvant are known to enhance immune responses,” Sina Bavari, director of science at USAMRIID, said. “Adjuvants, such as PIKA, activate innate immune signaling and may be used to elicit a more robust immune response to the vaccine.”